Surfactant protein-A reduces binding and phagocytosis of pneumocystis carinii by human alveolar macrophages in vitro

Am J Respir Cell Mol Biol. 1998 Jun;18(6):834-43. doi: 10.1165/ajrcmb.18.6.3059.

Abstract

Surfactant protein-A (SP-A) levels are increased in Pneumocystis carinii pneumonia, but the role of SP-A in the pathogenesis of P. carinii pneumonia is not completely understood. This study investigated the effect of SP-A on the in vitro binding and phagocytosis of P. carinii by normal human alveolar macrophages (AM). Determination of binding and phagocytosis was done with a fluorescence-based assay, utilizing fluorescein isothiocyanate (FITC)-labeled P. carinii. Binding and phagocytosis of P. carinii to AM correlated inversely with the levels of SP-A present on the surface of the organisms (r = -0.6323, P = 0.0086; and r = -0.9827, P < 0.0001, respectively). The addition of exogenous SP-A to organisms with low surface-associated SP-A reduced P. carinii binding by 30% (P < 0.05) and reduced phagocytosis by 20% (P < 0.05), whereas this effect was reversed with ethylenediamine tetraacetic acid (EDTA) or anti-SP-A antibody. Furthermore, binding and phagocytosis were enhanced after enzymatic removal of P. carinii surface-associated SP-A, and this effect was reversed with the addition of exogenous SP-A. The observed inhibitory effect of SP-A on P. carinii binding and phagocytosis reflected binding of SP-A to the organisms rather than a direct effect of SP-A on the macrophages. These data suggest that increased levels of SP-A may contribute to the pathogenesis of P. carinii pneumonia through binding to the surface of the organism and interfering with AM recognition of this opportunistic pulmonary pathogen.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Candida albicans / metabolism
  • Cells, Cultured
  • Edetic Acid / pharmacology
  • Glycoproteins / immunology
  • Glycoproteins / metabolism
  • Glycoproteins / pharmacology
  • Humans
  • Hydrolases / pharmacology
  • Immunoglobulin G / pharmacology
  • Macrophages, Alveolar / drug effects
  • Macrophages, Alveolar / physiology*
  • Phagocytosis / drug effects
  • Pneumocystis / metabolism*
  • Proteolipids / immunology
  • Proteolipids / metabolism*
  • Proteolipids / pharmacology
  • Pulmonary Surfactant-Associated Protein A
  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants / immunology
  • Pulmonary Surfactants / metabolism*
  • Pulmonary Surfactants / pharmacology
  • Time Factors

Substances

  • Glycoproteins
  • Immunoglobulin G
  • Proteolipids
  • Pulmonary Surfactant-Associated Protein A
  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants
  • zymolyase
  • Edetic Acid
  • Hydrolases